Geckin Büsra, Zoodsma Martijn, Kilic Gizem, Debisarun Priya A, Rakshit Srabanti, Adiga Vasista, Ahmed Asma, Parthiban Chaitra, Kumar Nirutha Chetan, D'Souza George, Baltissen Marijke P, Martens Joost H A, Domínguez-Andrés Jorge, Li Yang, Vyakarnam Annapurna, Netea Mihai G
Department of Internal Medicine, Radboud Center for Infectious Diseases, Radboud University Medical Centre, Nijmegen, The Netherlands.
Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Microbiol Spectr. 2023 Feb 13;11(2):e0023123. doi: 10.1128/spectrum.00231-23.
During the coronavirus disease 2019 (COVID-19) pandemic, large differences in susceptibility and mortality due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported between populations in Europe and South Asia. While both host and environmental factors (including Mycobacterium bovis BCG vaccination) have been proposed to explain this, the potential biological substrate of these differences is unknown. We purified peripheral blood mononuclear cells from individuals living in India and the Netherlands at baseline and 10 to 12 weeks after BCG vaccination. We compared chromatin accessibility between the two populations at baseline, as well as gene transcription profiles and cytokine production capacities upon stimulation. The chromatin accessibility of genes important for adaptive immunity was higher in the Indians than in the Europeans, while the latter had more accessible chromatin regions in genes of the innate immune system. At the transcriptional level, we observed that the Indian volunteers displayed a more tolerant immune response to stimulation, in contrast to a more exaggerated response in the Europeans. BCG vaccination strengthened the tolerance program in the Indians but not in the Europeans. These differences may partly explain the different impact of COVID-19 on the two populations. In this study, we assessed the differences in immune responses in individuals from India and Europe. This aspect is of great relevance, because of the described differences in morbidity and mortality between India and Europe during the pandemic. We found a significant difference in chromatin accessibility in immune cells from the two populations, followed by a more balanced and effective response in individuals from India. These exciting findings represent a very important piece of the puzzle for understanding the COVID-19 pandemic at a global level.
在2019年冠状病毒病(COVID-19)大流行期间,有报道称欧洲和南亚人群在感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)后的易感性和死亡率存在巨大差异。虽然宿主和环境因素(包括卡介苗接种)都被认为可以解释这种差异,但其潜在的生物学基础尚不清楚。我们在基线时以及卡介苗接种后10至12周,从生活在印度和荷兰的个体中纯化外周血单核细胞。我们比较了两个群体在基线时的染色质可及性,以及刺激后的基因转录谱和细胞因子产生能力。对适应性免疫重要的基因的染色质可及性在印度人中高于欧洲人,而后者在先天免疫系统基因中有更多可及的染色质区域。在转录水平上,我们观察到印度志愿者对刺激表现出更耐受的免疫反应,而欧洲人的反应则更为夸张。卡介苗接种增强了印度人的耐受程序,但在欧洲人中没有。这些差异可能部分解释了COVID-19对这两个人群的不同影响。在这项研究中,我们评估了来自印度和欧洲的个体在免疫反应上的差异。这一方面具有重要意义,因为在大流行期间印度和欧洲在发病率和死亡率方面存在上述差异。我们发现这两个人群的免疫细胞在染色质可及性方面存在显著差异,随后印度个体的反应更为平衡和有效。这些令人兴奋的发现是在全球层面理解COVID-19大流行这一难题中非常重要的一部分。
Asian Pac J Allergy Immunol. 2020-9
Cytokine Growth Factor Rev. 2020-7-1
Clin Transl Immunology. 2025-1-25
Trends Immunol. 2022-2
Lancet Infect Dis. 2022-1
Science. 2020-9-30